AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03748485
Drug: adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),with adjuvant chemotherapy
Trial: NCT00050622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03841526
Drug: Glugaon RTU Injection Without Insulin Pump Reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg injection without pump reduction
Trial: NCT01715272
Drug: Fleet enema
RxNorm normalized name: Fleet Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00268463
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capecitabine 850 mg/m2 twice daily on days 1-14 every 21 days for 8 cycles: Arm 1~Oral capecitabine 850 mg/m2 twice daily on days 22-35 every 42 days for 4 cycles and then on days 1-14 every 21 days for 4 cycles: Arm 2
Trial: NCT00517218
Drug: Genasense® (, oblimersen sodium G3139)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00405561
Drug: AMT2003
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00153179
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT02336048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to tocilizumab will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
Trial: NCT03371251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC administration
Trial: NCT01068613
Drug: QAX028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAX028 60 mcg via inhalation device
Trial: NCT01068613
Drug: QAX028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAX028 20 mcg via inhalation device
Trial: NCT01068613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to QAX028 via inhalation device
Trial: NCT02726334
Drug: BNC101 Solution for Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration: Administered via IV infusion once a week over 60 minutes (1 hour).
Trial: NCT01473264
Drug: recombinant human CC10 (rhCC10)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
Trial: NCT01473264
Drug: recombinant human CC10 (rhCC10)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg
Trial: NCT01473264
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half normal saline solution; single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
Trial: NCT01782924
Drug: KHK4827
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01040845
Drug: Norethindrone/Ethinyl Estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
Trial: NCT02025049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mannitol-based DP-b99 look-alike
Trial: NCT00503698
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected s.c (under the skin)
Trial: NCT01364012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab matching placebo will be administered IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
Trial: NCT00682786
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00471679
Drug: ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00371579
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03644342
Drug: Nirapaib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (see treatment regimen and method of treatment assignment)
Trial: NCT01941615
Drug: Microgynon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral doses for 23 days (period A+B)
Trial: NCT02654054
Drug: Placebo for Estradiol/Norethindrone Acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT02654054
Drug: Estradiol/Norethindrone Acetate
RxNorm normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
Trial: NCT00420420
Drug: MK0249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.
Trial: NCT00420420
Drug: Comparator: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period
Trial: NCT02364765
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour
Trial: NCT01777282
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Trial: NCT01777282
Drug: Alpha-glucosidase inhibitor
RxNorm normalized name: Alpha-glucosidase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Trial: NCT01215773
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching to HEA 200 mg tablet, oral administration
Trial: NCT02201004
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT01760889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule a day for 26 weeks
Trial: NCT01845441
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
Trial: NCT00170781
Drug: Lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04274933
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet; Oral
Trial: NCT01381211
Drug: 90Y-RE
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glass Yttrium-90 microspheres (TheraSphere®; MDS Nordion Inc.) will be used
Trial: NCT02573597
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous or bolus administration
Trial: NCT01235754
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily transdermal placebo gel
Trial: NCT04753008
Drug: Dopamine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of dopamine (3 mcg/kg/min) as part of cardiac support therapy after the cardiopulmonary bypass. Administration of dopamine is a subject of clinical decision based on the cardiovascular status of the patients.
Trial: NCT01052480
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.
Trial: NCT01992172
Drug: Photocil for Atopic Dermatitis
RxNorm normalized name: Atopica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photocil for Atopic Dermatitis
Trial: NCT02281799
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be commenced on an alternative thiopurine to that used initially, according to the standard dosing schedule used by their IBD clinician.~For example, if the initial thiopurine-related pancreatitis occurred while taking Azathioprine, the patient will be restarted on 6-MP, and vice versa.
Trial: NCT04819581
Drug: SP-103
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine topical system 5.4%
Trial: NCT01587274
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500mg twice/ day x 10 days
Trial: NCT04300881
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following intravitreal ocriplasmin therapy
Trial: NCT02372110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cellulose placebo capsules filled with acidophilus powder will be administered to subjects who are randomly assigned to the placebo condition
Trial: NCT00739882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered at Study Day (SD) 1, Week (W) 1, W 4, W 8 and W 12. Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week for 12 weeks (double-blind phase)
Trial: NCT04381520
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm, patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
Trial: NCT00289887
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.
Trial: NCT00711243
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
Trial: NCT00982787
Drug: Botanical extract from Passiflora incarnata
RxNorm normalized name: Passiflora incarnata extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: Liquid Passiflora extract~Dosage: 10ml (equivalent of 2.2 g of dried Passiflora)~Frequency: Once/Twice a day~Duration: 11 week intervention period
Trial: NCT03511105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to GSK2798745 will be available as white to slightly colored, round biconvex tablet to be administered via the oral route.
Trial: NCT00026988
Drug: Creatine
RxNorm normalized name: Creatine
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01692626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied twice daily for four weeks on opposite side of the face from the Pimecrolimus side.
Trial: NCT04115319
Drug: SEP363856
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule
Trial: NCT00562848
Drug: GSK962040
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.
Trial: NCT00562848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo.
Trial: NCT03642262
Drug: Mucinex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucinex® 600 mg single dose ER bi-layer tablet
Trial: NCT02681861
Drug: ASP6294 Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV)
Trial: NCT02681861
Drug: ASP6294 Subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC)
Trial: NCT02681861
Drug: Placebo Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV)
Trial: NCT02681861
Drug: Placebo Subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC)
Trial: NCT04603872
Drug: CD19/BCMA Targeted CAR T-cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.
Trial: NCT04618523
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin-based combination treatment
Trial: NCT03242408
Drug: LPCN 1021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate
Trial: NCT01365819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
Trial: NCT03825939
Drug: Intravenous Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV 0.9% sterile saline
Trial: NCT01159808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo capsules, oral administration, single dose
Trial: NCT02377271
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment by bosentan or placebo is randomized
Trial: NCT01975675
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDV/SOF 90/400 mg FDC tablet administered orally once daily
Trial: NCT03639987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT03772340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT04423757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 1358894 taken orally as three film-coated tablets once a day in the morning for six weeks.
Trial: NCT02571491
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: at doses of 0.3 mcg / kg / min during and until the end of the surgical operation
Trial: NCT02673736
Drug: PLX73086
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00902772
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mg, oral dose
Trial: NCT00902772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02884050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-active placebo
Trial: NCT01608750
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg/day, oral, 28 days
Trial: NCT00289848
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks
Trial: NCT01352572
Drug: antidepressant non-response
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants administration for 6 weeks under therapeutic dose nonresponders
Trial: NCT03941808
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
Trial: NCT04319471
Drug: Capecitabine/S-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Capecitabine/S-1
Trial: NCT04319471
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000mg/m2) D1 D8+ nidaplatinum (80-100mg/m2) D2 q3w ×4-6cycle
Trial: NCT00086229
Drug: Glucosamine
RxNorm normalized name: Glucosamine
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03426592
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing oleic acid. Over-encapsulated to mimic vitamin D3 capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study.
Trial: NCT03775525
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: antimetabolite
Trial: NCT01211834
Drug: DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
Trial: NCT01211834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously over 1 hour infusion every 4weeks
Trial: NCT01211834
Drug: DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate(MTX) and/or 1 DMARDs
Trial: NCT02162134
Drug: Inj. Ketorolac 30 mg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period.
Trial: NCT02162134
Drug: Inj. Zantac 50mg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
Trial: NCT04689035
Drug: AVLX-144
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug
Trial: NCT04689035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01387087
Drug: ASP015K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01387087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01195194
Drug: PRE-TRANSPLANT (PRE=before)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).~Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter.~Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL).
Trial: NCT02142504
Drug: Placebo (Saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching norovirus bivalent VLP vaccine
Trial: NCT02120352
Drug: ABC/3TC Oral tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC
Trial: NCT02120352
Drug: RPV Oral Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104
Trial: NCT03461185
Drug: Anti-Angiogenic Drugs
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib
Trial: NCT00971633
Drug: Comparator: Treatment A (Zofran, ondansetron)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)
Trial: NCT00971633
Drug: Comparator: Treatment B (Zofran, ondansetron)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single 8 mg tablet of Zofran marketed in the U.K., taken PO
Trial: NCT00971633
Drug: Comparator: Treatment C (Zofran, ondansetron)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
Trial: NCT01754597
Drug: Peptide Natriurétique de type B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide Natriurétique de type B
Trial: NCT01918488
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiloride tablet 20 mg two times daily (morning and afternoon) for two consecutive days.
Trial: NCT01654185
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet per day
Trial: NCT03658785
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.